With FDA decision near, Novartis bolsters SMA gene therapy case

With FDA decision near, Novartis bolsters SMA gene therapy case

Source: 
Biopharma Dive
snippet: 

Zolgensma could be approved by the FDA within weeks. Fresh clinical data give further evidence of the therapy's benefit, although reports of two deaths may invite questions.